Solis Mammography Joins Sarah Cannon Early Cancer Detection StudyAugust 13, 2018< Back To News
McKinney, TX, August 13, 2018– Sarah Cannon, the Cancer Institute of HCA Healthcare, announced today that Solis Mammography will participate in a study called STRIVE, which focuses on developing a test for early cancer detection. The STRIVE Study is designed to determine if a blood test can complement mammography screenings by identifying genomic material arising from tumors to help discover breast and other cancers at earlier stages.
“As a national leader in breast wellness and with our proud 30-year history of innovation, Solis Mammography is pleased to participate in the STRIVE Study with Sarah Cannon,” said James Polfreman, CEO and president of Solis Mammography. “Participation in clinical research is key in helping to develop new technologies that will benefit our patients.”
The study, sponsored by GRAIL, Inc., is seeking to enroll 120,000 women across participating sites. Women who volunteer to participate will provide a blood sample and complete a short questionnaire at the time of their regular screening mammogram. In addition, participants will be followed and their health records will be monitored for up to five years for new cancer diagnoses.
“By participating in this exciting research effort, women in our communities will help GRAIL scientists in their efforts to develop a test that is intended to enhance our ability to detect cancer at earlier and more treatable stages,” said Dax Kurbegov, MD, principal investigator of the STRIVE Study at Sarah Cannon and Vice President and Physician-in-Chief of Clinical Programs for Sarah Cannon. “The study is designed to help identify tiny fragments of genomic material that may signal the presence of breast or other cancers, and may help guide healthcare decisions by providing more information and reducing uncertainty.”
The study is being offered to women undergoing screening mammograms at multiple Sarah Cannon locations. For more information on the STRIVE Study, to see the full list of participating sites or to learn if you might be eligible to join, women can visit JoinSTRIVE.com, email STRIVE@sarahcannon.com or call 1-833-I-STRIVE (833-478-7483).
About Solis Mammography
The nation’s largest independent provider of breast screening and diagnostic services, Solis Mammography has been solely dedicated to providing superior breast care, helping women achieve and maintain optimal health and peace of mind for more than 30 years. As a pioneer and innovator in 3D mammography and as an early leader in providing SmartCurve comfort technology throughout all our centers, Solis Mammography continues to stay at the forefront of breast health. Headquartered in Addison, Texas, we serve patients across North Texas; Houston, Texas; Phoenix, Arizona; Columbus, Ohio; Greensboro, North Carolina, Philadelphia, Pennsylvania; and, through our affiliated brand, Washington Radiology, Washington, D.C., Maryland and Virginia. Solis Mammography operates both wholly owned centers and multiple successful joint ventures with hospital partners. Performing nearly 700,000 procedures each year in more than 50 center locations, both Solis Mammography and Washington Radiology offer breast screening and diagnostic mammography (2D and 3D), computer-aided detection, breast ultrasound, stereotactic biopsy, ultrasound-guided biopsy and bone density scanning.
About Sarah Cannon
Sarah Cannon, the Cancer Institute of HCA Healthcare, offers integrated cancer services with convenient access to cutting-edge therapies for those facing cancer in communities across the United States and United Kingdom. Sarah Cannon’s cancer programs include individualized patient navigation provided by oncology-trained nurses, more than 1,000 stem cell transplants performed annually throughout the Sarah Cannon Blood Cancer Network, hundreds of clinical trials, and molecular profiling capabilities. Through its services, Sarah Cannon is providing state-of-the-art cancer care close to home for hundreds of thousands of patients, a number unmatched by any single cancer center. To learn more about Sarah Cannon, visit sarahcannon.com.
GRAIL is a healthcare company whose mission is to detect cancer early, when it can be cured. GRAIL is using the power of high-intensity sequencing, population-scale clinical studies, and state-of-the-art computer science and data science to enhance the scientific understanding of cancer biology, and to develop and commercialize pioneering products for the early detection of cancer. The company is located in Menlo Park, California and Hong Kong. It is supported by leading global investors and pharmaceutical, technology, and healthcare companies. For more information, please visit www.grail.com.